OR WAIT null SECS
Sanofi is collaborating with Blackstone Life Sciences to accelerate the development of a treatment for multiple myeloma.
Sanofi and Blackstone Life Sciences announced on March 15, 2022 a €300 million (USD 331 million) collaboration focused on accelerating the development for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa (isatuximab), a treatment for patients with multiple myeloma.
Funds will be managed by Blackstone Life Sciences, and Sanofi will continue to manage the clinical program and retain full rights and control of Sarclisa. The study for the subcutaneous formulation is expected to begin in late 2022. If the studies and clinical development program are successful, Blackstone will be eligible to receive royalties on future sales.
Sanofi will partner with drug delivery company Enable Injections to advance the development of a subcutaneous delivery for Sarclisa. Sarclisa has already received regulatory approval for intravenous administration to treat patients with relapsed multiple myeloma. The treatment is under investigation for the possibility to treat other hematologic malignancies and solid tumors.
“The collaboration with Blackstone will accelerate our ability to offer patients a subcutaneous anti-CD38 antibody therapy that we believe will be innovative and more convenient,” commented John Reed, MD, PhD, Global Head of Research and Development for Sanofi, in the press release. “We are committed to building an industry-leading, sustainable pipeline with a steady stream of new therapies that have the potential to transform the practice of medicine.”